article thumbnail

FDA extends review of GSK’s myelofibrosis drug

Pharmaceutical Technology

UK-based pharmaceutical giant GSK has announced that the US Food and Drug Administration (FDA) has extended the review period of its new drug application (NDA) for the rare bone cancer drug momelotinib by three months. The drug is not currently approved in any markets globally.

article thumbnail

FDA withdraws approval of preterm birth drug Makena

Pharmaceutical Technology

The US Food and Drug Administration (FDA) has rescinded its approval for Swiss drug maker Covis Pharma’s (Covis) Makena drug and its generic versions , the only approved treatments aimed at reducing the risk of premature birth.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA withdraws approval of preterm birth drug Makena

Pharmaceutical Technology

The US Food and Drug Administration (FDA) has rescinded its approval for Swiss drug maker Covis Pharma’s (Covis) Makena drug and its generic versions , the only approved treatments aimed at reducing the risk of premature birth.

article thumbnail

Thursday pharma headlines

World of DTC Marketing

Merck’s old drugs are under more scrutiny, and anti-vaxxers are causing problems by cherry-picking unreliable information. regulators knew about reports of suicidal behavior in men taking the anti-baldness treatment Propecia when they decided not to warn consumers of those potential risks in a 2011 update of the popular drug’s label.

Pharma 180
article thumbnail

Strengthening and transforming the pharmaceutical supply chain

European Pharmaceutical Review

A recent report from the US Food and Drug Administration (FDA) shows that while the number of new drug shortages has fallen significantly from a high of 250 in 2011 to 49 in 2022, there was an increase in new drug shortages year-on-year.

article thumbnail

Re-engineering proteins to develop novel immunotherapies

European Pharmaceutical Review

Protein engineering comes with several challenges, including maintaining stability and immunogenicity of the novel protein and creating an inherently active drug. The molecule is a stable fusion protein that is administered as an active drug and does not degrade into native IL-2 inside the body. 2011; 117(11): 2993–3001.

article thumbnail

The future of targeted alpha therapy development and manufacture

European Pharmaceutical Review

Based on these promising results, the US Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to AlphaMedix in February 2024. Orano Med is now building industrial facilities throughout the world for the commercialisation its drugs.